ChromaDex (CDXC) - Company Sales Revenue

ChromaDex - graphic logo of issuer CDXC

The sales structure and volume of ChromaDex Corporation (CDXC) exhibit volatility driven by a dependence on NAD+ patents and Tru Niagen licenses. Stability is provided by the wellness sector's loyalty during crises, while growth is fueled by biotechnological developments in longevity. The value of 0.10 expresses today's metric value, helping the investor assess the asset's liquidity and fundamental stability to avoid freezing capital in a weakening business.

ChromaDex Corp. (CDXC) - Company Revenue from 07/04/2022 to 03/19/2025

Comprehensive metric breakdowns and analytics for ChromaDex Corp (CDXC)

- market capitalization indicators:
Summary company analysis:ChromaDex CDXC
Signature product of ChromaDex Corp.

The business scaling dynamics of ChromaDex Corporation (CDXC) are clearly reflected in the company's commercial revenue, confirming high consumer loyalty to the science-driven Tru Niagen products. This indicator captures the daily cash inflow from sales, allowing investors to assess the fundamental stability of demand and timely rebalance their portfolios should a negative trend in sales volumes emerge.